Clinical significance of serum matrix metalloproteinase-13 levels in patients with localized scleroderma

Clinical and Experimental Rheumatology

Volumn 24, Issue 4, 2006, Pages 394-399

  Asano, Yoshihide ^b   Ihn, Hironobu ^a   Kubo, Masahide ^b   Jinnin, Masatoshi ^b   Mimura, Yoshihiro ^b   Ashida, Ryuichi ^b   Tamaki, Kunihiko ^b  

^a KUMAMOTO UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Localized scleroderma; Matrix metalloproteinase 13; Skeletal muscle; Systemic sclerosis

Indexed keywords

COLLAGENASE 3;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; DISEASE MARKER; DISEASE SEVERITY; ENZYME ASSAY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; INFANT; LINEAR SCLERODERMA; LOCALIZED SCLERODERMA; MALE; MORPHEA; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; MALE; MATRIX METALLOPROTEINASE 13; MIDDLE AGED; MUSCLE, SKELETAL; SCLERODERMA, LOCALIZED;

EID: 33748525166     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. JABLONSKA S, RODNAN GP: Localized forms of scleroderma. Clin Rheum Dis 1979; 5: 215-41.
2. TUFFANELLI DL, WINKELMANN RK: Systemic scleroderma. Arch Dermatol 1955; 84: 359-71.
3. ASANO Y, IHN H, YAMANE K, JINNIN M, MIMURA Y, TAMAKI K: Differential effects of the immunosuppressant FK-506 on human a2(I) collagen gene expression and transforming growth factor b signaling in normal and scleroderma fibroblasts. Arthritis Rheum 2005; 52: 1237-47.
4. KUBO M, IHN H, YAMANE K, TAMAKI K: Upregulated expression of transforming growth factor b receptors in dermal fibroblasts in skin sections from patients with localized scleroderma. Arthritis Rheum 2001; 44: 731-4.
5. KORN JH: What's wrong with the scleroderma fibroblast? Clin Exp Rheumatol 2004; 22 (Suppl. 33): S64-5.
6. TROJANOWSKA M: What did we learn by studying scleroderma fibroblasts? Clin Exp Rheumatol 2004; 22 (Suppl. 33): S59-63.
7. TAKEHARA K, SATO S: Localized scleroderma is an autoimmune disorder. Rheumatology 2005; 44: 274-9.
8. KAHALEH B: Immunologic aspects of scleroderma. Curr Opin Rheumatol 1993; 5: 760-5.
9. KAHARI VM, SANDBERG M, KALIMO H, VUORIO T, VUORIO E: Identification of fibroblasts responsible for increased collagen production in localized scleroderma by in situ hybridization. J Invest Dermatol 1988; 90: 664-70.
10. GRUSS C, REED JA, ALTMEYER P, McNUTT NS, KERSCHER M: Induction of interstitial collagenase (MMP-1) by UVA-1 phototherapy in morphea fibroblasts. Lancet 1997; 350: 1295-6.
11. MATTILA L, AIROLA K, AHONEN M et al.: Activation of tissue inhibitor of metalloproteinases-3 (TIMP-3) mRNA expression in scleroderma skin fibroblasts. J Invest Dermatol 1998; 110: 416-21.
12. FREIJE JMP, DIEZ-ITZA I, BALBIN M et al.: Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas. J Biol Chem 1994; 269: 16766-73.
13. KNAUPER V, LOPEZ-OTIN C, SMITH B, KNIGHT G, MURPHY G: Biochemical characterization of human collagenase-3. J Biol Chem 1996; 271: 1544-50.
14. LEEMAN MF, CURRAN S, MURRAY GI: The structure, regulation, and function of human matrix metalloproteinase-13. Crit Rev Biochem Mol Biol 2002; 37: 149-66.
15. JOHANSSON N, VAALAMO M, GRENMAN S et al.: Collagenase-3 (MMP-13) is expressed by tumor cells in invasive vulvar squamous cell carcinomas. Am J Pathol 1997; 154: 469-80.
16. AIROLA K, JOHANSSON N, KARINIEMI AL, KAHARI VM, SAARIALHO-KERE U: Human collagenase-3 is expressed in malignant squamous epithelium of the skin. J Invest Dermatol 1997; 109: 225-31.
17. NAKOPOULOU L, GIANNOPOULOU I, GAKIOPOULOU H, LIAPIS H, TZONOU A, DAVARIS PS: Matrix metalloproteinase-1 and -3 in breast cancer: correlation with progesterone receptors and other clinicopathologic features. Hum Pathol 1999; 30: 436-42.
18. NIELSEN BS, RANK F, LOPEZ JM et al.: Collagenase-3 expression in breast myofibroblasts as a molecular marker of transition of ductal carcinoma in situ lesions to invasive ductal carcinomas. Cancer Res 2001; 61: 7091-100.
19. LEEMAN MF, MCKAY JA, MURRAY GI: Matrix metalloproteinase 13 activity is associated with poor prognosis in colorectal cancer. J Clin Pathol 2002; 55: 758-62.
20. KONTTINEN YT, SALO T, HANEMAAIJER R et al.: Collagenase 3 (MMP-13) and its activators in rheumatoid arthritis: localization in the pannus-hard tissue junction and inhibition by alendronate. Matrix Biol 1999; 18: 401-12.
21. PETROW PK, WERNICKE D, SCHULZE WESTHOFF C et al.: Characterisation of the cell type-specificity of collagenase 3 mRNA expression in comparison with membrane type 1 matrix metalloproteinase and gelatinase A in the synovial membrane in rheumatoid arthritis. Ann Rheum Dis 2002; 61: 391-7.
22. ITOH T, UZUKI M, SHIMAMURA T, SAWAI T: Dynamics of matrix metalloproteinase (MMP)-13 in the patients with rheumatoid arthritis. Ryumachi 2002; 42: 60-9.
23. ASANO Y, IHN H, KUBO M et al.: Clinical significance of serum levels of matrix metalloproteinase-13 in patients with systemic sclerosis. Rheumatology (in press).
24. SATO S, FUJIMOTO M, IHN H, KIKUCHI K, TAKEHARA K: Clinical characteristics associated with antihistone antibodies in patients with localized scleroderma. J Am Acad Dermatol 1994; 31: 567-71.
25. TAKEHARA K, MOROI Y, NAKABAYASHI Y, ISHIBASHI Y: Antinuclear antibodies in localized scleroderma. Arthritis Rheum 1989; 26: 612-6.
26. SATO S, IHN H, SOMA Y et al.: Antihistone antibodies in patient with localized scleroderma. Arthritis Rheum 1993; 36: 1137-41.
27. IHN H, YAZAWA N, KUBO M et al.: Circulating levels of soluble CD30 are increased in patients with localized scleroderma and correlated with serological and clinical features of the disease. J Rheumatol 2000; 27: 698-702.
28. RAVANTI L, HAKKINEN L, LARJAVA H et al: Transforming growth factor-b induces collagenase-3 expression by human gingival fibroblasts via p38 mitogen-activated protein kinase. J Biol Chem 1999; 274: 37292-300.
29. RAVANTI L, TORISEVA M, PENTTINEN R et al.: Expression of human collagenase-3 (MMP-13) by fetal skin fibroblasts is induced by transforming growth factor β via p38 mitogen-activated protein kinase. FASEB J 2001; 15: 1098-100.
30. LEIVONEN SK, CHANTRY A, HAKKINEN L, HAN J, KAHARI VM: Smad3 mediates transforming growth factor-β-induced collagenase-3 (matrix metalloproteinase-13) expression in human gingival fibroblasts. Evidence for cross-talk between Smad3 and p38 signaling pathways. J Biol Chem 2002; 277: 46338-46.
31. URIA JA, JIMENEZ MG, BALBIN M, FREIJE JM, LOPEZ-OTIN C: Differential effects of transforming growth factor-b on the expression of collagenase-1 and collagenase-3 in human fibroblasts. J Biol Chem 1998; 273: 9769-77.
32. VAALAMO M, MATTILA L, JOHANSSON N et al.: Distinct populations of stromal cells express collagenase-3 (MMP-13) and collagenase-1 (MMP-1) in chronic ulcers but not in normally healing wounds. J Invest Dermatol 1997; 109: 96-101.
33. RAVANTI L, HEINO J, LOPEZ-OTIN C, KAHARI VM: Induction of collagenase-3 (MMP-13) expression in human skin fibroblasts by three-dimensional collagen is mediated by p38 mitogen-activated protein kinase. J Biol Chem 1999; 274: 2446-55.